A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-01-01

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The researchers hope to explore the etiological distribution and influencing factors of KCNQ2-related neonatal convulsions or refractory epileptic encephalopathy, and to improve the level of assessment, identification, intervention and shunt of KCNQ2-related convulsions. To formulate countermeasures and measures for prevention, management and health education.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genotype, Phenotype, and Disease Progression of Developmental Epileptic Encephalopathy With Onset Before 2 Years of Age

NCT06278428

Epilepsy; Seizure Child Development Gene Abnormality +1 more

RECRUITING

Molecular Genetic Mechanisms of Infantile Epilepsies and the Impact of Genetic Diagnosis

NCT06701084

Neonatal Epilepsy Infantile Epilepsy

RECRUITING NA

A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy

NCT05407727

SCN2A-DEE Epilepsy

COMPLETED

Clinical-genetic Investigations in Children With Early Infantile Epilepsies

NCT01357707

Epilepsy Seizures, Infantile

COMPLETED

Pathophysiology Based Therapy of Early Onset Epileptic Encephalopathies

NCT02968966

Seizure, Epileptic

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Convulsion is the most common clinical manifestation of neonatal central nervous system dysfunction. the incidence of convulsion is very high in neonatal period, especially in the first week after birth. the incidence of convulsion decreases gradually with the increase of age. The incidence of convulsion reported by Bassan et al was 1.5 ‰ \~ 3.5 ‰ in term infants and 10% ≤ 130% in premature infants. Most of the neonatal convulsions suggest that there are serious primary diseases in the body. in addition to hypoxic-ischemic encephalopathy, intracranial hemorrhage and infection, a large number of studies have proved that genetic factors play a key role in the occurrence of neonatal convulsions and epileptic encephalopathy in infants. Nearly 20% to 50% of neonatal convulsions are idiopathic convulsions. it has been thought that KCNQ2 gene, a potassium channel subunit located in 20q11.3, and KCNQ3 gene, another potassium channel subunit located in 8q24, are mutated. Is the molecular basis for some benign familial neonatal convulsions, Usually the prognosis is good, but with the expansion of the study sample, investigators found that KCNQ2 may be associated with refractory epileptic encephalopathy, and there are few international reports in this regard. The study of KCNQ2 gene has led to a new understanding of the etiology of neonatal convulsion. The researchers hope to explore the etiological distribution and influencing factors of KCNQ2-related neonatal convulsions or refractory epileptic encephalopathy, and to improve the level of assessment, identification, intervention and shunt of KCNQ2-related convulsions. To formulate countermeasures and measures for prevention, management and health education.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Seizures Seizure Disorder Seizure Newborn Seizures, Generalized Epileptic Encephalopathy Epileptic Encephalopathy, Neonatal-onset Epileptic Encephalopathy, Infant-onset KCNQ2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

infants with seizure with KCNQ2 gene mutation.

Infants who met the inclusion criteria were enrolled in this study. The infants will get their own DNA sequencing results by WES technology. The researchers found that some of them carried mutations in the KCNQ2 gene. so they wanted to compare whether there were differences with or without KCNQ2 gene mutations in the efficacy of anticonvulsants or long-term neurodevelopment in different exposure groups.

KCNQ2

Intervention Type GENETIC

The researchers extracted DNA from the baby's serum and sent it to WES to get the baby's total exon sequence.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

KCNQ2

The researchers extracted DNA from the baby's serum and sent it to WES to get the baby's total exon sequence.

Intervention Type GENETIC

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary or initial convulsion
* Postnatal age \<28 days.
* Seizure in the neonatal period
* Informed consent of parents

Exclusion Criteria

* Seizure caused by congenital cerebral hypoplasia or multiple structural malformations.
* Seizure caused by other system-related syndromes.
* Seizure caused by perinatal or postpartum factors such as HIE, infection, intracranial hemorrhage, etc.

Minimum Eligible Age

0 Days

Maximum Eligible Age

28 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No